Compositions of anti-interleukin 12/interleukin 23 antibody

A pharmaceutical composition comprising:

• anti-interleukin 12 (IL-12)/interleukin 23 (TL-23) antibodies comprising:
• a heavy chain comprising a CDRH1, CDRH2, and CDRH3, wherein the amino acid sequence of the CDRH1, CDRH2 and CDRH3 is SEQ ID NO:
• 1, 2 and 3, respectively;
• and
• a light chain comprising a CDRL1, CDRL2, and CDRL3, wherein the amino acid sequence of the CDRL1, CDRL2, and CDRL3 is SEQ ID NO:
• 4, 5 and 6, respectively,
• wherein
• (a) the light chain comprises W32 (EU numbering), wherein at least 1% and no more than 2% of the light chains of the composition comprise oxidized W32;
• and/or
• (b) the heavy chain comprises position D55 (EU numbering), and wherein greater than 6% and no more than 14.3% of said antibodies comprise isoaspartic acid at heavy chain position 55, or greater than 6% and no more than 14%, or greater than 7% and no more than 14% of said antibodies comprise isoaspartic acid at heavy chain position 55;
• and/or
• (c) at least 0.4% and no more than 5.0%, or at least 0.4% and no more than 1.0% of said antibodies of the pharmaceutical composition are comprised by high molecular weight species selected from dimers, oligomers, and dimers and oligomers;
• and/or
• (d) at least 1.8% and no more than 6.4%, or greater than 1.8% and no more than 6.4%, or at least 2.0% and no more than 6.4%, or at least 1.8% and no more than 3.7%, or greater than 1.8% and no more than 3.7%, or at least 2.0% and no more than 3.7% of said antibodies of the pharmaceutical composition comprise high mannose;
• and/or
• (e) at least 26.5% and no more than 58%, or at least 26.5% and no more than 29.5%, or at least 26.5% and no more than 29%, or at least 27% and no more than 58%, or at least 27% and no more than 29.5%, or at least 27% and no more than 29% of said antibodies of the pharmaceutical composition comprise sialylation;
• and/or
• (f) the composition comprises a total of at least 28.0%, or at least 28.0% and no more than 60.3% acidic peak species, or at least 28.0% and no more than 58.3% acidic peak species, or at least 28% and no more than 55.0% acidic peak species as determined by cation exchange high performance liquid chromatography (CEX-HPLC);
• and/or
• (g) the heavy chain comprises W33 (EU numbered 0, wherein at least 0.1% and no more than 0.8%, or at least 0.2% and no more than 0.8%, at least 0.1% and no more than 0.4%, or at least 0.2% and no more than 0.4% of the heavy chains of the composition comprise oxidized W33.